Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Gilead Sciences $4.3 billion acquisition of CymaBay Therapeutics
We are advising Gilead Sciences on the acquisition
Eli Lilly $6.5 billion notes offering
The investment-grade notes are due 2027, 2029, 2034, 2054 and 2064
Novo Nordisk acquisition of certain Catalent sites from Novo Holdings
We are advising Novo Nordisk on the acquisition
Immunocore Holdings $402.5 million convertible notes offering
The 2.5% convertible notes are due 2030
Greenway Health $375 million refinancing
We advised the administrative agent, arrangers and bookrunners on the financing
Immatics $201 million follow-on offering
We advised Immatics on the offering of shares
IDEAYA Biosciences $350 million at-the-market offering
The shares are listed on the Nasdaq Global Select Market
Alector $75 million stock offering
The common stock is listed on the Nasdaq Global Select Market
Sun Pharmaceutical enters into merger agreement with Taro Pharmaceutical
We are advising Sun Pharma on the transaction
Roche $295 million acquisition of LumiraDx's point of care technology platform
We are advising Roche on the acquisition